[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-359300-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-359300-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","recent-advances-in-the-role-of-long-non-coding-rnas-in-ovarian-cancer-chemoresistance-review","Recent advances in the role of long non-coding RNAs in ovarian cancer chemoresistance - Review","","Ovarian cancer remains a major cause of cancer mortality in women, with limited five-year survival and frequent relapse after initial response to surgery and systemic chemotherapy. This review addresses the urgent need to clarify molecular drivers of chemoresistance and to identify innovative counterstrategies. Long noncoding RNAs (lncRNAs), as emerging transcriptional regulators, show aberrant expression and mutations linked to tumorigenesis, metastasis, and drug resistance. Mechanistic evidence connects lncRNAs to multiple chemoresistance pathways, including ceRNA crosstalk, epigenetic control, metabolic effects, impaired DNA repair, and signaling modulation, influencing cisplatin, carboplatin, and paclitaxel efficacy.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/recent-advances-in-the-role-of-long-non-coding-rnas-in-ovarian-cancer-chemoresistance-review/359300/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/recent-advances-in-the-role-of-long-non-coding-rnas-in-ovarian-cancer-chemoresistance-review/359300.png","ImageObject",300,407,{"name":42,"@type":43},"Jacob","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is chemoresistance a critical obstacle in ovarian cancer treatment?","Question",{"text":63,"@type":64},"Although many patients initially respond to chemotherapy, a large proportion eventually relapse due to drug resistance. This substantially limits long-term clinical outcomes and effectiveness of standard regimens.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What roles can long non-coding RNAs (lncRNAs) play in ovarian cancer chemoresistance?",{"text":68,"@type":64},"lncRNAs contribute through mechanisms such as acting as competing endogenous RNAs (ceRNAs), regulating epigenetic processes, influencing metabolism, impairing DNA damage repair, and modulating key signaling pathways.",{"name":70,"@type":61,"acceptedAnswer":71},"How might lncRNAs be used to improve ovarian cancer therapy?",{"text":72,"@type":64},"lncRNAs are discussed as promising biomarkers and therapeutic targets. By clarifying their mechanistic involvement, the review aims to provide new perspectives and pathways to address chemoresistance.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},359300,1790192990,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":109,"preview_page_count":33,"preview_urls":145},962084931830,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Dong et al. Journal of Ovarian Research (2026) 19:131  \n[https://doi.org/10.1186/s13048-026-02041-w](https://doi.org/10.1186/s13048-026-02041-w)  \nJournal of Ovarian Research  \nREVIEW Open Access  \nRecent advances in the role  \nof long non-coding RNAs in ovarian cancer chemoresistance  \nShanshan Dong1, Hongtao Fu2 and Qian Gong1*  \nAbstract  \nOvarian cancer (OC) remains a leading cause of cancer-related mortality among women, with a persistently low five-year survival rate. Currently, the primary treatment modalities for OC include surgery and systemic chemotherapy. However, despite initial therapeutic efficacy, the majority of patients eventually experience relapse and drug resistance, severely limiting clinical outcomes. Consequently, there is an urgent need to elucidate the molecular mechanisms underlying OC and develop innovative strategies to overcome chemoresistance. Long noncoding RNAs (lncRNAs), emerging as novel transcriptional regulators, exhibit aberrant expression and mutations closely associated with tumorigenesis, metastasis, and drug resistance. As promising biomarkers and therapeutic targets, lncRNAs hold significant potential for advancing cancer treatment. Growing evidence indicates that lncRNAs contribute to chemoresistance in OC through various mechanisms, including functioning as competing endogenous RNAs (ceRNAs) to sequester miRNAs, participating in epigenetic regulation, influencing metabolism, impairing DNA damage repair, and modulating key signaling pathways, thereby affecting the efficacy of cisplatin, carboplatin, and paclitaxel. This review summarizes the mechanistic roles and recent advances in lncRNA research related to OC chemoresistance, aiming to provide novel perspectives and pathways to address this clinical challenge.  \nKeywords LncRNA, Ovarian cancer, Chemoresistance, Research advances  \n*Correspondence:  \nQian Gong  \n[gongqian@hnca.org.cn](gongqian@hnca.org.cn)  \n1Drug Clinical Research Center, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China  \n2Department of Breast Surgery, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha 410013, China  \nIntroduction  \nOvarian cancer (OC), one of the most common malignancies of the female reproductive system, ranks third in incidence among gynecological cancers. Due to its asymptomatic early stages and limitations in diagnostic and therapeutic strategies, a significant number of OC patients are diagnosed at advanced stages, rendering OC the fifth leading cause of cancer-related mortality in women globally. The current standard treatment for OC involves cytoreductive surgery combined with platinumbased chemotherapy. Although most patients initially respond well to chemotherapy, achieving substantial survival benefits, approximately 70% of these individuals eventually experience relapse, with chemoresistance  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http","cbCailEKAwk7k84j","https://ap.wps.com/l/cbCailEKAwk7k84j","pdf",5149360,16,"English","# Abstract\n# Introduction\n# lncRNA overview and tumor drug resistance","[{\"question\":\"Why is chemoresistance a critical obstacle in ovarian cancer treatment?\",\"answer\":\"Although many patients initially respond to chemotherapy, a large proportion eventually relapse due to drug resistance. This substantially limits long-term clinical outcomes and effectiveness of standard regimens.\"},{\"question\":\"What roles can long non-coding RNAs (lncRNAs) play in ovarian cancer chemoresistance?\",\"answer\":\"lncRNAs contribute through mechanisms such as acting as competing endogenous RNAs (ceRNAs), regulating epigenetic processes, influencing metabolism, impairing DNA damage repair, and modulating key signaling pathways.\"},{\"question\":\"How might lncRNAs be used to improve ovarian cancer therapy?\",\"answer\":\"lncRNAs are discussed as promising biomarkers and therapeutic targets. By clarifying their mechanistic involvement, the review aims to provide new perspectives and pathways to address chemoresistance.\"}]","Recent advances in the role of long non-coding RNAs in ovarian cancer chemoresistance - Review | PDF",1790136641,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f0253ee948df4f02db120b19e4e594ca.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/18d1091cdef0366350bba1126b4acb93.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2b3ea07c9cba02eb5cf3035f12e8e28c.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9ac1a69f796633ac0bdf5929ad0a8e6e.webp",980,1306]